Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OROS Methylphenidate HCl in Children with ADHD
NCT00269815Phase 3Completed
- Sponsor
- ALZA Corporation
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of methylphenidate osmotic release oral system in attention deficit hyperactivity disorder (ADHD), sponsored by ALZA Corporation. Primary endpoints: Incidence of adverse events at 27 months, Changes in physical examinations at 27 months and 5 more. Status: completed.
02
Drugs
methylphenidate osmotic release oral system
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00269815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269815.